Published in final edited form as:

Angew Chem Int Ed Engl. 2009 ; 48(13): 2379–2382. doi:10.1002/anie.200805455.

Total Synthesis of Indolizidine Alkaloid (–)-209D: Overriding Substrate Bias in the Asymmetric Rhodium-Catalyzed [2+2+2] Cycloaddition**

Robert T. Yu [Dr.], Ernest E. Lee, Guillaume Malik [Prof.], and Tomislav Rovis

*Department of Chemistry, Colorado State University, Fort Collins, CO 80523, Fax: (+1) 970-491-1801

Robert T. Yu ; Ernest E. Lee ; Guillaume Malik ; Tomislav Rovis: rovis@lamar.colostate.edu

Abstract

CO! You had me at hello The use of chiral biphenyl-based phosphoramidite ligands on rhodium provides an efficient [2+2+2] cycloaddition between terminal alkyl alkynes and alkenyl isocyanates. The cycloaddition proceeds through a CO migration pathway, and facilitates a rapid four-step asymmetric synthesis of indolizidine (–)-209D.

Keywords

CO migration; cycloaddition; indolizidine alkaloids; isocyanates; phosphoramidites

Indolizidine frameworks possessing an alkyl group substituted at the 5-position (indolizidine numbering)[i] represent a large class of naturally occurring compounds.[ii] Alkaloids ranging from structurally simple indolizidine 167B and 209D to more complex marine alkaloids such as cylindricines[iii] (Scheme 1) and the immunosuppressant FR901483[iv] all contain such

**We thank NIGMS (GM080442), Eli Lilly, Boehringer Ingelheim and Johnson & Johnson for support. TR is a fellow of the Alfred P. Sloan Foundation and thanks the Monfort Family Foundation for a Monfort Professorship.

Correspondence to: Tomislav Rovis, rovis@lamar.colostate.edu.

Supporting information for this article is available on the WWW under <http://www.angewandte.org> or from the author.

ring systems. Most recently, Weinreb and coworkers described the first total synthesis of secu'amamine A, a novel tetracyclic alkaloid, via a 5-alkyl indolizinone as a late-stage intermediate.[v] Herein, we detail the development of an enantioselective rhodium-catalyzed [2+2+2] cycloaddition of terminal alkyl alkynes and alkenyl isocyanates to generate various 5-alkyl indolizinones (**3**). As part of a program directed toward developing a universal strategy to indolizidine alkaloids, the synthetic utility here is demonstrated by an expedient synthesis of (–)-209D.

We have been exploring the use of neutral rhodium(I)/TADDOL-derived phosphoramidite complexes as enantioselective catalysts for various [2+2+2] cycloadditions, including reactions of terminal alkynes with isocyanates[vi] or carbodiimides.[vii] In previous studies, the use of terminal alkyl alkynes with these catalysts provide efficient cycloadditions to afford various bicyclic lactams **4** (Scheme 1) in good yields and enantioselectivities, while the 5-alkyl indolizinone cycloadducts **3**, resulting from a CO migration process, can only be observed as minor components. In this work, we report a new Rh-L system to achieve a catalyst-controlled cycloaddition en route to 5-alkyl indolizinones **3**.

To tune product selectivity through ligand design, we began our study by examining the cycloaddition of 1-octyne **1a** and alkenyl isocyanate **2** with various phosphoramidite ligands [viii] (Table 1). Switching from TADDOL-derived ligands such as **L1** to BINOL-derived **L2** led to a complete inversion of product selectivity (entry 1 vs. 2) favoring the indolizinone **3a**. Formation of **3** is thought to proceed through the initial metalacycle **I** followed by a CO migration process via **II** to arrive at **III**. Migratory insertion of the pendant alkene into Rh-N bond followed by reductive elimination gives rise to cycloadducts **3**. Selectivity in the formation of two initial metalacycles (**I** vs. **IV**) is reflected in the product selectivity between **3** and **4**. Despite the low yield and poor *ee*, the fundamental difference in product selectivity prompted further investigation into BINOL-derived phosphoramidites. Ligands possessing substitution at the 3,3'-positions of the BINOL backbone positively impact reaction efficiency toward the desired indolizinone **3a**. Further exploration led to the discovery of GUIPHOS (**L3**). This TMS-substituted phosphoramidite **L3** provides a much improved reaction with product selectivity ~4:1, good chemical yield, and most importantly an excellent 96% *ee* for **3a** (entry 3). Although the TMS-substituted biphenol-derived phosphoramidite **L4** behaves no differently than GUIPHOS (entry 4), the corresponding ligand possessing *tert*-butyl groups at the 3,3'-positions (**L5**)[ix],[x] proved superior. Precatalyst $[\text{Rh}(\text{C}_2\text{H}_4)_2\text{Cl}]_2$ modified with **L5** provides a clean reaction to furnish the desired indolizinone **3a** with a good product ratio (6.2:1) in excellent yield and enantioselectivity (entry 5).

Indolizidine 209D belongs to a family of 22 natural products, commonly referred to as gephyrotoxins, isolated from the skin secretions of neotropical frogs.[xi] Along with indolizidine 167B (Scheme 1), these two structurally simpler alkaloids have only been isolated in minute quantities from unidentified dendrobatid frogs found in a single population. Over the years, they have attracted much interest from the synthetic community, both to prepare them in greater quantities as well as a tool to validate new methodologies. [xii] In our own effort, the key intermediate 5-hexyl indolizinone **3a** can be prepared conveniently by the

cycloaddition protocol in one step and is suitable for scale-up (Scheme 2). The resulting vinylogous amide functionality readily undergoes a diastereoselective hydrogenation to afford enantioenriched amino alcohol **5** as a single diastereomer. Barton-McCombie deoxygenation via **6** completes the four-step enantioselective synthesis of (–)-209D, which also confirms the absolute configuration of **3a**: $[\alpha]^{22}_{\text{D}} = -66.5^\circ$ (c 1.0, CH_2Cl_2); lit.^[10a] $[\alpha]^{26}_{\text{D}} = -80.4^\circ$ (c 1.0, CH_2Cl_2). Considering that alkenyl isocyanate **2** can be prepared in one step from commercially available 5-hexenoic acid, this constitutes the shortest synthesis of 209D reported to date.^[10]

The newly developed Rh/phosphoramidite **L5** catalyst promotes the enantioselective synthesis of 5-alkyl indolizinones very efficiently (Table 2). Alkyl alkynes bearing an array of functional groups including ester, chloride, silyl ether, Weinreb amide, unprotected terminal alkyne, and phenyl ring all react smoothly to afford cycloadducts in good product ratios and excellent enantioselectivities (entries 2 – 7). The cycloaddition is highly sensitive to both electronic and steric effects on the alkyne partner. The product selectivity shifts more toward formation of the bicyclic lactams **4** with electron-withdrawing substituents closer to the alkynyl center. For example, cycloaddition of 3-phenyl-1-propyne **1h** gave a product ratio of 3:1 favoring the benzyl-substituted indolizinone **3h**, instead of the ratio of 5:1 obtained with **1g** (entry 8 vs. entry 7). In a more extreme case, cycloaddition of TIPS-protected propargyl alcohol **1i** furnishes a 1.6:1 product mixture slightly favoring the indolizinone **3i** (entry 9). On the other hand, reaction with the more sterically hindered alkyne **1j** improves the product selectivity to provide the desired cycloadduct **3j** in a high yield and excellent enantioselectivity (entry 10). In fact, bulky alkynes such as cyclohexyl and cyclopentyl acetylenes are among the best cycloaddition partners. The corresponding indolizinone products **3k** and **3l** can be obtained in high yields and enantioselectivities with excellent product ratios of 14:1 (entries 11, 12). Even more impressively, the rhodium catalyst modified by ligand **L5** promotes the cycloaddition of tertiary alkyl-substituted alkynes to gain access to highly congested 5-alkyl indolizinones (entries 13, 14). For example, the MOM-protected cyclopentanol-substituted cycloadduct **3m** can be produced in 60% yield with a slightly diminished 81% enantioselectivity as the only product. In general, cycloaddition with the *tert*-butyl substituted phosphoramidite **L5** produces the best product selectivity and high overall reactivity, while the use of GUIPHOS (**L3**) usually gives the best level of enantiocontrol. Although GUIPHOS (**L3**) displays low reactivity toward most sterically hindered alkynes (**3k**: 44% yield, 95% ee; **3m**: 23% yield, 80% ee), it does provide an efficient cycloaddition for the formation of *tert*-butyl substituted indolizinone **3n** in a good chemical yield and enantioselectivity (entry 15). This protocol can also be applied to the synthesis of 5,9-dialkyl indolizinones (eq. 1). 1,1-Disubstituted alkenyl isocyanate **7** participates in the cycloadditions with 1-octyne **1a** quite efficiently to provide the corresponding cycloadduct **8** in good product ratio and isolated yield. Interestingly, while the product selectivity stays relatively unchanged as those obtained with the unsubstituted alkenyl isocyanate **2**, a profound effect on the enantioselectivity is observed. The use of GUIPHOS (**L3**) here provides a partial solution, improving the enantioselectivity significantly.

(1)

In conclusion, we have developed an efficient catalyst system that promotes a cycloaddition between terminal alkyl alkynes and alkenyl isocyanates involving a CO migration process. This previously unattainable process allows access to various 5-alkyl indolizinones including

an enantioselective synthesis of indolizidine (–)-209D. Further studies on the reaction scope as well as applications to the synthesis of alkaloids are ongoing.

Experimental Section

General procedure: In an inert atmosphere (N_2) glove box, a flame-dried round bottom flask was charged with $[Rh(C_2H_4)_2Cl]_2$ (2.6 mg, 0.0068 mmol) and the phosphoramidite ligand **L5** (5.8 mg, 0.0136 mmol), and was fitted with a flame-dried reflux condenser. The system was sealed with a standard septum. Upon removal from the glove box, 1.0 ml toluene was added via syringe and the resulting yellow solution was stirred at ambient temperature under argon flow for 5 minutes. To this solution was added a solution of alkyne **1** (0.54 mmol) and isocyanate **2** (30 mg, 0.27 mmol) in 2 ml of toluene via syringe. After an additional 1 ml of toluene was added to wash down the remaining residue, the resulting solution was heated to 110 °C in an oil bath, and maintained at reflux for 12 h. The reaction mixture was cooled to ambient temperature, concentrated *in vacuo*, and purified by column chromatography.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

References

- i. Crabb TA, Newton RF, Jackson D. Chem Rev 1971;71:109–126.
- ii. a) Michael JP. Nat Prod Rep 2005;22:603–626. [PubMed: 16193159] b) Michael JP. Nat Prod Rep 2007;24:191–222. [PubMed: 17268613] c) Michael JP. Nat Prod Rep 2008;25:139–165. [PubMed: 18250900]
- iii. For a recent review on cylindricines, see: Weinreb SM. Chem Rev 2006;106:2531–2549.2549 [PubMed: 16771458]
- iv. For total syntheses, see: a)Snider BB, Lin H. J Am Chem Soc 1999;121:7778–7786.7786b)Scheffler G, Seike H, Sorensen EJ. Angew Chem Int Ed 2000;39:4593–4596.4596c)Ousmer M, Braun NA, Bavoux C, Perrin M, Ciufolini MA. J Am Chem Soc 2001;123:7534–7538.7538 [PubMed: 11480973]d)Maeng J, Funk RL. Org Lett 2001;3:1125–1128.1128 [PubMed: 11348175]e)Kan T, Fujimoto T, Ieda S, Asoh Y, Kitaoka H, Fukuyama T. Org Lett 2004;6:2729–2731.2731 [PubMed: 15281755]
- v. Liu P, Hong S, Weinreb SM. J Am Chem Soc 2008;130:7562–7563. [PubMed: 18491903]
- vi. a) Yu RT, Rovis T. J Am Chem Soc 2006;128:12370–12371. [PubMed: 16984159] b) Lee EE, Rovis T. Org Lett 2008;10:1231–1234. [PubMed: 18284249]For our first report in this area, see: Yu RT, Rovis T. J Am Chem Soc 2006;128:2782–2783.2783 [PubMed: 16506740]
- vii. Yu RT, Rovis T. J Am Chem Soc 2008;130:3262–3263. [PubMed: 18302377]
- viii. a) de Vries AHM, Meetsma A, Feringa BL. Angew Chem Int Ed 1996;35:2374–2376. b) Feringa BL. Acc Chem Res 2000;33:346–353. [PubMed: 10891052] c) Alexakis A, Burton J, Vastra J, Benhaim C, Fournieux X, van den Heuvel A, Leveque J, Maze F, Rosset S. Eur J Org Chem 2000:4011–4028. d) Panella L, Feringa BL, de Vries JG, Minnaard AJ. Org Lett 2005;7:4177–4180. [PubMed: 16146381]
- ix. Phosphoramidites based on Biphen (3,3'-di-tert-butyl-5,5',6,6'-tetramethyl-1,1'-biphenyl-2,2'-diol) have been prepared and used successfully in asymmetric hydroformylation and hydrogenation: a) Hua Z, Vassar VC, Choi H, Ojima I. Proc Natl Acad Sci USA 2004;101:5411. [PubMed: 15020764] b)Giacomina F, Meetsma A, Panella L, Lefort L, de Vries AHM, de Vries JG. Angew Chem Int Ed 2007;46:1497–1500.1500
- x. Both enantiomers of the bisphenol required for the synthesis of **L5** are commercially available.
- xi. a) Daly JW. Fortschr Chem Org Naturst 1982;41:205. [PubMed: 7049875] b) Aronstam RS, Daly JW, Spande TF, Narayanan TK, Albuquerque EX. Neurochem Res 1986;11:1227. [PubMed: 2431336]
- xii. For asymmetric syntheses of indolizidine 209D, see: a)Polniaszek RP, Belmont SE. J Org Chem 1990;55:4688–4693.4693b)Jefford CW, Wang JB. Tetrahedron Lett 1993;34:3119–3122.3122c)

Åhman J, Somfai P. Tetrahedron Lett 1995;36:303–306.306d)Åhman J, Somfai P. Tetrahedron 1995;51:9747–9756.9756e)Nukui S, Sodeoka M, Sasai H, Shibasaki M. J Org Chem 1995;60:398–404.404f)Jefford CW, Sienkiewicz K, Thornton SR. Helv Chim Acta 1995;78:1511–1524.1524g)Takahata H, Kubota M, Ihara K, Okamoto N, Momose T, Azer N, Eldefrawi AT, Eldefrawi ME. Tetrahedron: Asymmetry 1998;9:3289–3301.3301h)Chênevert R, Ziarani GM, Morin MP, Dasser M. Tetrahedron: Asymmetry 1999;10:3117–3122.3122i)Yamazaki N, Ito T, Kibayashi C. Org Lett 2000;2:465–467.467 [PubMed: 10814352]j)Back TG, Nakajima K. J Org Chem 2000;65:4543–4552.4552 [PubMed: 10959857]k)Kim G, Jung S, Kim W. Org Lett 2001;3:2985–2987.2987 [PubMed: 11554824]l)Reddy PG, Baskaran S. J Org Chem 2004;69:3093–3101.3101 [PubMed: 15104448]

Scheme 1.

[2+2+2] Cycloaddition strategies to the framework of various indolizidine alkaloids.

Scheme 2.
Synthesis of indolizidine (–)-209D.
^aSee entry 1, Table 2.

Table 1Ligand effect on product selectivity and enantioselectivity.^[a]

entry	L	3 : 4 ^[b]	yield (%) of 3 ^[c]	ee (%) of 3 ^[d]
1	L1	1 : 3.2	20	73 ^[e]
2	L2	2.2 : 1	22	72
3	L3	3.8 : 1	60	96
4	L4	3.5 : 1	50	94
5	L5	6.2 : 1	75	91

(-)-L1	(R)-L2	(R)-L3 (GUIPHOS)	(R)-L4 (R=TMS) (R)-L5 (R=t-Bu)

^[a] Conditions: **1** (2 equiv), **2** (0.27 mmol), Rh/L in PhMe (0.07 M) at 110 °C.^[b] Product selectivity determined by ¹H NMR of the unpurified mixture.^[c] Isolated yield.^[d] Determined by HPLC using a chiral stationary phase.^[e] Other enantiomer.

Table 2Enantioselective synthesis of 5-alkyl indolizinones.^[a]

entry

Major Product

1^[e]

2

3

entry

Major Product

4

entry

Major Product

5

entry

Major Product

6

entry

Major Product

entry

Major Product

9

10

11

12

Major Product

entry

Major Product

14

15^[f]

^[a] Conditions: **1** (2 equiv), **2** (0.27 mmol), Rh/**L** in PhMe (0.07 M) at 110 °C.

^[b] Product selectivity determined by ^1H NMR of the unpurified mixture.

^[c] Isolated yield.

^[d] Determined by HPLC using a chiral stationary phase.

^[e] 1.4 mmol scale (**2**) at 100 °C.

^[f] GUIPHOS (**L3**) used as the ligand.